# TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension

> **NCT07350070** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 78 (estimated)

## Conditions studied

- HCC
- Liver Cirrhosis
- Portal Hypertension

## Interventions

- **DRUG:** TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol

## Key facts

- **NCT ID:** NCT07350070
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07350070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07350070, "TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07350070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*